resiquimod has been researched along with Melanoma in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Geary, SM; Naguib, YW; Salem, AK; Tambunlertchai, S | 2 |
| Allred, JB; Block, MS; Markovic, SN; Nevala, WK; Pang, YP; Strand, C | 1 |
| Ambrosini, M; Bruijns, SC; de Gruijl, TD; Fehres, CM; Hooijberg, E; Kalay, H; Unger, WW; van Beelen, AJ; van Kooyk, Y | 1 |
| Cooper, ZA; Dai, Z; Huang, XF; Hwu, P; Khong, H; Overwijk, WW; Singh, M; Vasilakos, JP; Wargo, JA | 1 |
| Adams, S; Bhardwaj, N; Chiriboga, L; Cruz, CM; Darvishian, F; Escalon, J; Escano, C; Gnjatic, S; Goldberg, J; Hasan, F; Holman, RM; Jungbluth, A; Mandeli, J; Muren, C; Ott, PA; Pan, L; Pavlick, A; Rolnitzsky, L; Sabado, RL; Sharpe, D; Spadaccia, M; Vasilakos, JP; Vengco, I; Venhaus, R; Yepes, E | 1 |
| Bong, AB; Drewniok, C; Eberle, J; Geilen, CC; Gollnick, H; Schön, M; Schön, MP; Wienrich, BG | 1 |
3 trial(s) available for resiquimod and Melanoma
| Article | Year |
|---|---|
A pilot clinical trial testing topical resiquimod and a xenopeptide as immune adjuvants for a melanoma vaccine targeting MART-1.
Topics: Administration, Topical; Aged; Cancer Vaccines; CD8-Positive T-Lymphocytes; Combined Modality Therapy; Cytokines; Female; Gene Products, gag; HLA-A2 Antigen; Humans; Imidazoles; Male; MART-1 Antigen; Melanoma; Middle Aged; Peptide Fragments; Pilot Projects; Skin Neoplasms | 2019 |
Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanoma.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antibodies, Neoplasm; Antibody Formation; Antigens, Neoplasm; Cancer Vaccines; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Female; Humans; Imidazoles; Immunity, Cellular; Male; Mannitol; Melanoma; Membrane Proteins; Middle Aged; Oleic Acids; Peptide Fragments; Vaccination | 2015 |
Death receptor-independent apoptosis in malignant melanoma induced by the small-molecule immune response modifier imiquimod.
Topics: Administration, Topical; Aminoquinolines; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Biopsy; Cell Line, Tumor; fas Receptor; Humans; Imidazoles; Imiquimod; Melanocytes; Melanoma; Membrane Glycoproteins; Proto-Oncogene Proteins c-bcl-2; Receptors, Tumor Necrosis Factor; Skin Neoplasms; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha | 2004 |
4 other study(ies) available for resiquimod and Melanoma
| Article | Year |
|---|---|
Investigating silver nanoparticles and resiquimod as a local melanoma treatment.
Topics: Animals; CD8-Positive T-Lymphocytes; Melanoma; Metal Nanoparticles; Mice; Silver | 2023 |
Anti-melanoma Effects of Resiquimod (RSQ) In Vitro and in Combination with Immune Checkpoint Blockade In Vivo.
Topics: Animals; Immune Checkpoint Inhibitors; Immunotherapy; Melanoma; Mice; Skin Neoplasms; Tumor Microenvironment | 2023 |
Topical rather than intradermal application of the TLR7 ligand imiquimod leads to human dermal dendritic cell maturation and CD8+ T-cell cross-priming.
Topics: Administration, Topical; Aminoquinolines; Cancer Vaccines; CD8-Positive T-Lymphocytes; Cross-Priming; Cytokines; Dendritic Cells; Humans; Imidazoles; Imiquimod; Injections, Intradermal; Ligands; MART-1 Antigen; Melanoma; Skin; Toll-Like Receptor 7 | 2014 |
Effective innate and adaptive antimelanoma immunity through localized TLR7/8 activation.
Topics: Adaptive Immunity; Animals; Antibodies, Monoclonal; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Chemokine CCL2; CTLA-4 Antigen; Cytotoxicity, Immunologic; Imidazoles; Immunity, Innate; Injections, Intralesional; Leukocytes; Lymphocytes, Tumor-Infiltrating; Melanoma; Melanoma, Experimental; Mice; Nitric Oxide; Phenotype; Toll-Like Receptor 7; Toll-Like Receptor 8; Tumor Burden | 2014 |